NO20054855L - Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav - Google Patents
Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter deravInfo
- Publication number
- NO20054855L NO20054855L NO20054855A NO20054855A NO20054855L NO 20054855 L NO20054855 L NO 20054855L NO 20054855 A NO20054855 A NO 20054855A NO 20054855 A NO20054855 A NO 20054855A NO 20054855 L NO20054855 L NO 20054855L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl ether
- retinal
- retinal nerve
- contraceptive
- remedy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Et alkyleterderivat representert ved den generelle formel [1] eller dens salt: hvor R1 og R2 hver representerer en substituent så som hydrogen, halogen eller alkyl; R3 representerer alkylamino, amino eller hydroksyl; ringen A representerer en 5- eller 6-leddet aromatisk heterosyklisk gruppe eller en benzenring; m og n er hver et helt tall på fra 1 til 6; og p er et helt tall på fra 1 til 3; viser en effekt ved å beskytte retinale nerveceller og er derfor anvendelige som et forebyggende og/eller behandlende middel for retinale nervesykdommer så som glaukom, diabetisk retinopati, retinal arterie-obstruksjon, retinal venøs obstruksjon, makuladegenerasjon og retinopati ved prematuritet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003112539 | 2003-04-17 | ||
PCT/JP2004/005355 WO2004091605A1 (ja) | 2003-04-17 | 2004-04-15 | アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20054855D0 NO20054855D0 (no) | 2005-10-20 |
NO20054855L true NO20054855L (no) | 2006-01-09 |
NO334062B1 NO334062B1 (no) | 2013-12-02 |
Family
ID=33296058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054855A NO334062B1 (no) | 2003-04-17 | 2005-10-20 | Alkyleterderivater eller salter derav for behandling og/eller forebygging av retinale nervesykdommer |
Country Status (20)
Country | Link |
---|---|
US (3) | US20060205709A1 (no) |
EP (1) | EP1614419B1 (no) |
JP (1) | JP4642657B2 (no) |
KR (1) | KR101096528B1 (no) |
CN (1) | CN100353942C (no) |
AU (1) | AU2004229283B2 (no) |
BR (1) | BRPI0409398A (no) |
CA (1) | CA2521648C (no) |
CY (1) | CY1113248T1 (no) |
DK (1) | DK1614419T3 (no) |
ES (1) | ES2391273T3 (no) |
IL (1) | IL171388A (no) |
MX (1) | MXPA05011125A (no) |
NO (1) | NO334062B1 (no) |
NZ (1) | NZ543100A (no) |
PL (1) | PL1614419T3 (no) |
PT (1) | PT1614419E (no) |
SI (1) | SI1614419T1 (no) |
WO (1) | WO2004091605A1 (no) |
ZA (1) | ZA200508166B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230407B1 (hu) * | 2001-10-19 | 2016-04-28 | Toyama Chemical Co., Ltd. | Alkil-éter-származékok és sóik |
KR100935615B1 (ko) | 2002-06-14 | 2010-01-07 | 토야마 케미칼 컴퍼니 리미티드 | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 |
SG155251A1 (en) * | 2005-03-28 | 2009-09-30 | Toyama Chemical Co Ltd | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)- ethoxy)propyl)azetidin-3-ol or salts thereof |
US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
ZA200808728B (en) * | 2006-04-26 | 2010-01-27 | Toyama Chemical Co Ltd | Neurogenesis inducer or neuropathy Therapeutic agent comprising alkyl ether derivative or salt thereof |
SI2048145T1 (sl) * | 2006-08-04 | 2011-04-29 | Toyama Chemical Co Ltd | Spodbujevalec aktivnosti proteinske kinaze c, vsebujoäś derivat alkilnega etra ali sol le-tega |
BRPI0823084B1 (pt) * | 2008-07-14 | 2019-07-16 | Biocon Limited | Método de síntese de uma mistura de oligômeros substancialmente monodispersa |
ES2721666T3 (es) * | 2012-02-22 | 2019-08-02 | Fujifilm Toyama Chemical Co Ltd | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo |
AU2015211753B2 (en) * | 2014-01-31 | 2019-09-12 | Fujifilm Toyama Chemical Co., Ltd. | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
JP6761413B2 (ja) * | 2015-06-11 | 2020-09-23 | 富士フイルム富山化学株式会社 | シグマ受容体結合剤 |
EP3395342B1 (en) | 2015-12-25 | 2020-09-30 | FUJIFILM Toyama Chemical Co., Ltd. | Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof |
EP3563843A4 (en) | 2016-12-28 | 2019-12-11 | FUJIFILM Toyama Chemical Co., Ltd. | TOPICAL COMPOSITION |
NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
EP3632429A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR REDUCING AMYLOID PROTEIN CONTENT |
EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
CA3067453C (en) | 2017-06-02 | 2021-11-23 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
WO2019088083A1 (ja) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2521136A1 (fr) * | 1982-02-05 | 1983-08-12 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
DK74693D0 (da) * | 1993-06-23 | 1993-06-23 | Novo Nordisk As | Novel heterocyclic chemistry |
TW281667B (no) | 1994-02-03 | 1996-07-21 | Synthelabo | |
WO1997011054A1 (en) * | 1995-09-22 | 1997-03-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
JP4549452B2 (ja) * | 1997-12-12 | 2010-09-22 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤 |
EP1325744A4 (en) * | 2000-10-10 | 2005-08-17 | Toyama Chemical Co Ltd | REMEDIES FOR OPTICAL NERVE DISEASES CONTAINING 1,2-ETHANEDIOL DERIVATIVES OR CORRESPONDING SALTS |
US7199147B2 (en) * | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
HU230407B1 (hu) * | 2001-10-19 | 2016-04-28 | Toyama Chemical Co., Ltd. | Alkil-éter-származékok és sóik |
KR100935615B1 (ko) * | 2002-06-14 | 2010-01-07 | 토야마 케미칼 컴퍼니 리미티드 | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 |
-
2004
- 2004-04-15 SI SI200431955T patent/SI1614419T1/sl unknown
- 2004-04-15 MX MXPA05011125A patent/MXPA05011125A/es unknown
- 2004-04-15 ZA ZA200508166A patent/ZA200508166B/en unknown
- 2004-04-15 CA CA2521648A patent/CA2521648C/en not_active Expired - Fee Related
- 2004-04-15 ES ES04727697T patent/ES2391273T3/es not_active Expired - Lifetime
- 2004-04-15 PT PT04727697T patent/PT1614419E/pt unknown
- 2004-04-15 WO PCT/JP2004/005355 patent/WO2004091605A1/ja active Application Filing
- 2004-04-15 JP JP2005505437A patent/JP4642657B2/ja not_active Expired - Fee Related
- 2004-04-15 PL PL04727697T patent/PL1614419T3/pl unknown
- 2004-04-15 DK DK04727697.7T patent/DK1614419T3/da active
- 2004-04-15 NZ NZ543100A patent/NZ543100A/en unknown
- 2004-04-15 US US10/553,120 patent/US20060205709A1/en not_active Abandoned
- 2004-04-15 KR KR1020057019794A patent/KR101096528B1/ko not_active IP Right Cessation
- 2004-04-15 CN CNB2004800103801A patent/CN100353942C/zh not_active Expired - Fee Related
- 2004-04-15 BR BRPI0409398-4A patent/BRPI0409398A/pt not_active Application Discontinuation
- 2004-04-15 EP EP04727697A patent/EP1614419B1/en not_active Expired - Lifetime
- 2004-04-15 AU AU2004229283A patent/AU2004229283B2/en not_active Ceased
-
2005
- 2005-10-11 IL IL171388A patent/IL171388A/en not_active IP Right Cessation
- 2005-10-20 NO NO20054855A patent/NO334062B1/no not_active IP Right Cessation
-
2009
- 2009-08-17 US US12/542,074 patent/US7897594B2/en not_active Expired - Fee Related
-
2011
- 2011-01-19 US US13/008,982 patent/US8067406B2/en not_active Expired - Fee Related
-
2012
- 2012-10-23 CY CY20121100992T patent/CY1113248T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20110112066A1 (en) | 2011-05-12 |
ES2391273T3 (es) | 2012-11-23 |
WO2004091605A1 (ja) | 2004-10-28 |
EP1614419A4 (en) | 2010-08-18 |
IL171388A (en) | 2010-12-30 |
US7897594B2 (en) | 2011-03-01 |
PL1614419T3 (pl) | 2013-01-31 |
NZ543100A (en) | 2008-07-31 |
CN100353942C (zh) | 2007-12-12 |
MXPA05011125A (es) | 2005-12-14 |
JP4642657B2 (ja) | 2011-03-02 |
NO20054855D0 (no) | 2005-10-20 |
US20100075941A1 (en) | 2010-03-25 |
KR101096528B1 (ko) | 2011-12-20 |
US20060205709A1 (en) | 2006-09-14 |
AU2004229283B2 (en) | 2009-02-05 |
EP1614419B1 (en) | 2012-08-08 |
SI1614419T1 (sl) | 2012-12-31 |
CY1113248T1 (el) | 2016-04-13 |
NO334062B1 (no) | 2013-12-02 |
PT1614419E (pt) | 2012-10-22 |
ZA200508166B (en) | 2007-03-28 |
BRPI0409398A (pt) | 2006-04-18 |
AU2004229283A1 (en) | 2004-10-28 |
DK1614419T3 (da) | 2012-11-19 |
US8067406B2 (en) | 2011-11-29 |
CA2521648A1 (en) | 2004-10-28 |
KR20050123167A (ko) | 2005-12-29 |
CN1774245A (zh) | 2006-05-17 |
EP1614419A1 (en) | 2006-01-11 |
CA2521648C (en) | 2012-07-03 |
JPWO2004091605A1 (ja) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054855L (no) | Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav | |
CA3000483C (en) | Compounds, compositions, and methods for modulating cftr | |
NO20062370L (no) | Amidderivater | |
JP2008247898A (ja) | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 | |
TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
NO20041531L (no) | Alkyleterderivater eller salter derav | |
NO20055887L (no) | Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer | |
NO20063382L (no) | Nye kinolinderivater | |
NO20075409L (no) | Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater | |
NO20052038L (no) | Ny adeninforbindelse og anvendelse derav | |
NO20083542L (no) | Nye kumarinderivater med antitumoraktivitet | |
MX2009006024A (es) | Derivados de heteroaril piridopirimidona sustituidos. | |
NO20055632L (no) | Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater | |
NO20084872L (no) | 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig | |
BRPI0408189A (pt) | 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas | |
NO20072389L (no) | Substituerte benzokinolizinderivater | |
WO2004031160A3 (fr) | Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete | |
JPWO2004092179A1 (ja) | スピロ誘導体、製造法および抗酸化薬 | |
NO20063865L (no) | Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter | |
NO20075617L (no) | 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet | |
WO2009041566A1 (ja) | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 | |
EA200901402A1 (ru) | Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина | |
NO312296B1 (no) | Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat | |
BRPI0912171B1 (pt) | composto ativador de receptor de glicocorticoide, e, composição | |
CA3124838A1 (en) | Methods and formulations to treat mitochondrial dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |